

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, June 20, 2025

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	-
Bill Ladwig, RPh	X	Brandi Tackett, PharmD	X
Sarah McGill, PharmD	X	Deidra Van Gilder, PharmD, Chair	X
Jesse Nieuwenhuis, MD	X	Clarissa Barnes, MD, DSS Staff	X
Kelley Oehlke, PharmD	X	Mike Jockheck, DSS Staff	X
Lenny Petrik, PharmD	X	Taylor Koerner, DSS Staff	X
Heather Preuss, MD	X		

Administrative Business

Van Gilder called the meeting to order at 1:02 pm. Jockheck introduced new committee members Jesse Nieuwenhuis and Sarah McGill. Petrik will be leaving the committee. Van Gilder thanked him for his years of service. The minutes of the March meeting was presented. Ladwig made a motion to approve. Baack seconded the motion. The minutes were approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from January 1, 2025, to March 31, 2025. A total of 4,548 PAs were reviewed of which 104 requests (2.3%) were received via telephone, 130 requests (2.9%) were received via fax, 1,728 requests (38%) were reviewed electronically, and 2,585 requests (56.8%) were received via ePA. There was an increase of 18.5% in PAs and increase of 31% in appeals compared to the previous quarter. This increase of PAs and appeals from 4Q to 1Q were consistent as previous years.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from January 1, 2025, to March 31, 2025. The top five therapeutic classes based on paid amount were atypical antipsychotics, incretin mimetics, interleukin-mediated agents, immunomodulatory agents, and tumor necrosis factor inhibitors. These top 15 therapeutic classes comprise 18.85 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid constitute 9% of total claims. The drug Oxervate was new to the Top 50 drugs by paid amount.

Van Gilder inquired if there was any public comment. There were none.

Old Business

Fleqsuvy

Committee reviewed Fleqsuvy and baclofen utilization. Nieuwenhuis asked for clarification on generic baclofen suspension pricing compared to Fleqsuvy. Van Gilder inquired if there was any public comment. There were none. Van Gilder motioned to add PA on both the solution and suspension formulation for patients without dysphagia for trial of tablets first. Baack seconded motion. The motion was approved unanimously.

Opioid Update

The committee reviewed opioid outcomes compared to the previous quarter from the opioid initiatives. There was an increase in opioid utilization and utilizers during 1Q2025 with corresponding increase in total eligibility and utilizers. The average MME/day/utilizer stayed steady. Ladwig inquired about PMPM on opioid utilization. Jockheck replied state does not track PMPM on opioids specifically.

New Business**Calcitonin gene-related peptide (CGRP) review**

The committee reviewed the CGRP utilization and discussed the new guidance from the American Headache Society. Omer Aziz, Field Value, Evidence, and Outcomes Liaison from Teva, provided public comment. Van Gilder stated the current criteria is reasonable.

Antipsychotics review

Barnes provided background that monitoring for second generation antipsychotics (SGAs)s is a national metric. To improve the monitoring of SGAs, it was proposed to collect metabolic monitoring during PA reviews. Baack questioned on the delay in treatment and allowing for grace periods when prescribers do not have the requested monitoring information to submit with the PA reviews. Committee discussed extensively. Omer Aziz, Field Value, Evidence, and Outcomes Liaison from Teva, provided public comment. Stefan Luft, Senior Medical Science Liaison from Luye Pharma, provided public comment. Baack requested process and provider communication before implementing this program.

Journavx

Journavx clinical information was presented for review. Committee reviewed utilization and discussed. Taha Khan, Associate Director of HEOR, at Vertex Pharmaceuticals, provided public comment. Committee recommended monitoring utilization and review again.

Ohtuvayre

Ohtuvayre clinical information was presented for review. Van Gilder inquired if there was any public comment. There were none. Van Gilder recommended monitoring utilization and review again.

Adjournment

The next meeting is scheduled for September 26, 2025. The December and March meetings are tentatively scheduled for December 12, 2025, and March 27, 2026. All motioned and were in favor of adjourning the meeting. The meeting adjourned at 2:30 pm CT.